NKTR - Nektar Therapeutics
| Previous Close | 31.13 |
| Open | 30.97 |
| Bid | 31.47 x 3000 |
| Ask | 31.49 x 800 |
| Day's Range | 30.60 - 31.83 |
| 52 Week Range | 29.22 - 92.17 |
| Volume | 917,185 |
| Avg. Volume | 1,639,050 |
| Market Cap | 5.479B |
| Beta (3Y Monthly) | 3.62 |
| PE Ratio (TTM) | 8.33 |
| EPS (TTM) | 3.78 |
| Earnings Date | May 8, 2019 - May 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.18 |
- Reuters•23 hours ago
S&P 500 closes at record high, even as EPS growth stagnates
The widely followed S&P 500 marked its highest ever close, beating its previous record closing high on Sept. 20, and the Nasdaq beat its Aug. 29 all-time closing high. The S&P 500 has rallied 25% from Dec. 24, reversing a steep selloff caused by fears of higher interest rates and uncertainty around U.S. President Donald Trump's trade war with Beijing. The S&P 500 has slightly underperformed European stocks over the same time period.
- Insider Monkey•3 days ago
Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
GuruFocus.com•13 days agoThese 3 Falling Knives Are Expected to Outperform
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NKTR. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.
- CNBC•14 days ago
Analysts believe the stock market will set a record soon and these names are going to lead the way
Company analysts see the S&P 500 reaching 3,097, or 7% from here, over the next 12 months, according to calculations from FactSet. Based on the difference between the bottom-up target price and the current trading level, biopharmaceutical company Nektar Therapeutics is poised to have 110% upside by year-end. Advanced Micro Devices, Franklin Resources, Chipotle Mexican Grill, Xilinx and Waters Corp. are set to have double-digit losses.
- Associated Press•22 days ago
GameStop falls while Dave & Buster's and Blue Apron rise
Stocks that moved substantially or traded heavily on Wednesday: GameStop Corp., down 47 cents to $9.63 The video game retailer's first-quarter profit and revenue fell short of analysts' expectations and ...
- Simply Wall St.•22 days ago
A Look At Nektar Therapeutics's (NASDAQ:NKTR) Exceptional Fundamentals
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Attractive stocks have exceptional fundamentals. In the case of Nektar Therapeutics (NASDAQ:NKTR), there's...
- PR Newswire•23 days ago
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
SAN FRANCISCO , April 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential ...
- Markit•23 days ago
See what the IHS Markit Score report has to say about Nektar Therapeutics.
Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate Bearish sentimentShort interest | NeutralShort interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NKTR are favorable, with net inflows of $11.43 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Benzinga•23 days ago
The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
- American City Business Journals•24 days ago
Here are the typical employee salaries at Twitter, Salesforce, Yelp, Square, Zynga, Dolby and other tech companies
How much do Twitter, Salesforce and Yelp pay typical employees? See how it compares with CEO pay and where it stacks up among San Francisco's other top tech companies.
- PR Newswire•24 days ago
Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
OSLO, Norway and SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Vaccibody AS and Nektar Therapeutics (NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist. "We are excited to present these novel preclinical data that show combining bempeg with VB10.NEO synergize to increase both the breadth and the depth of the neoantigen-specific immune response. VB10.NEO is designed to specifically activate a patient's immune system to tumor-specific antigens, called neoantigens.
- Zacks•26 days ago
Nektar (NKTR) Down 17.1% Since Last Earnings Report: Can It Rebound?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•last month
3 Stocks That Could Double Your Money
Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.
- Zacks•2 months ago
Stock Market News For Mar 7, 2019
Benchmarks ended in the red on Wednesday after a slew of weak economic reports weighed on the markets.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NKTR earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Nektar Therapeutics Earnings Call
- PR Newswire•2 months ago
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference
SAN FRANCISCO , March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky , Ph.D., is scheduled to present at the Cowen and Company ...
- Investing.com•2 months ago
Biotech Companies Slump Midday With FDA Chief Set to Leave
Gottlieb said in a letter addressed to the agency that he is leaving to be with family.
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- GlobeNewswire•2 months ago
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic.
- GuruFocus.com•2 months ago
Nektar Therapeutics Inc (NKTR) Files 10-K for the Fiscal Year Ended on December 31, 2018
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. Nektar Therapeutics Inc had annual average EBITDA growth of 1.30% over the past ten years. Warning! GuruFocus has detected 3 Warning Signs with NKTR.
- PR Newswire•2 months ago
Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
SAN FRANCISCO , March 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study ...
- CNBC•2 months ago
Stocks making the biggest moves midday: Gap, Tesla, L Brands & more
Shares of Tesla fell 7.84 percent after the company's underwhelming announcement that it will be launching its standard Model 3. Barclays analyst Brian Johnson even called it the " un-iPhone moment ." The electric car maker also announced store closures and layoffs in an effort to reduce costs, in addition to stating that the company will not turn a profit during its first quarter. Nektar Therapeutics NKTR — The biopharmaceutical fell nearly 6 percent Friday after reporting fourth-quarter earnings.
- Zacks•2 months ago
Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended
Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.
Motley Fool•2 months agoNektar Therapeutics (NKTR) Q4 2018 Earnings Conference Call Transcript
NKTR earnings call for the period ending December 31, 2018.
